Today, Celgene Corp. (CELG) Cut to “Hold” at Vetr Inc.

Today, Celgene Corp. (CELG) Cut to “Hold” at Vetr Inc.

Celgene Corp. (NASDAQ:CELG) was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating in a research report issued on Monday. They presently have a $125.81 target price on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 4.52% from the company’s previous close.

A number of other research analysts also recently issued reports on the stock. Standpoint Research downgraded shares of Celgene Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, November 9th. Mizuho assumed coverage on shares of Celgene Corp. in a research report on Monday, November 7th. They issued a “buy” rating and a $130.00 price target on the stock. Zacks Investment Research upgraded shares of Celgene Corp. from a “hold” rating to a “buy” rating and set a $117.00 price target on the stock in a research report on Wednesday, November 2nd. BTIG Research restated a “buy” rating and issued a $138.00 price target on shares of Celgene Corp. in a research report on Monday, October 31st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $159.00 price target on shares of Celgene Corp. in a research report on Friday, October 28th. Five investment analysts have rated the stock with a hold rating and twenty-five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $136.34.

Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.63% on Monday, reaching $120.30. 3,357,961 shares of the company’s stock traded hands. The company has a 50 day moving average price of $108.88 and a 200 day moving average price of $106.73. The firm has a market capitalization of $93.26 billion, a price-to-earnings ratio of 45.69 and a beta of 1.71. Celgene Corp. has a 52 week low of $93.05 and a 52 week high of $127.00.

Celgene Corp. (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the Zacks’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The firm had revenue of $2.98 billion for the quarter, compared to the consensus estimate of $2.84 billion. During the same period in the prior year, the firm posted $1.23 EPS. The firm’s revenue was up 27.8% compared to the same quarter last year. On average, equities research analysts predict that Celgene Corp. will post $5.92 earnings per share for the current fiscal year.

In related news, Director Michael A. Friedman sold 18,600 shares of the business’s stock in a transaction on Wednesday, November 9th. The shares were sold at an average price of $116.10, for a total transaction of $2,159,460.00. Following the transaction, the director now owns 18,600 shares of the company’s stock, valued at $2,159,460. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Corp /De/ Celgene bought 800,150 shares of the company’s stock in a transaction that occurred on Monday, October 24th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. Corporate insiders own 0.97% of the company’s stock.

A number of institutional investors have recently made changes to their positions in CELG. First Financial Corp IN raised its stake in shares of Celgene Corp. by 30.9% in the third quarter. First Financial Corp IN now owns 967 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 228 shares during the period. Jolley Asset Management LLC raised its stake in shares of Celgene Corp. by 58.8% in the second quarter. Jolley Asset Management LLC now owns 1,215 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 450 shares during the period. Smithfield Trust Co. raised its stake in shares of Celgene Corp. by 12.5% in the second quarter. Smithfield Trust Co. now owns 1,282 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 142 shares during the period. Cornerstone Advisors Inc. raised its stake in shares of Celgene Corp. by 202.8% in the third quarter. Cornerstone Advisors Inc. now owns 1,320 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 884 shares during the period. Finally, Integrated Investment Consultants LLC raised its stake in shares of Celgene Corp. by 21.8% in the second quarter. Integrated Investment Consultants LLC now owns 1,339 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 240 shares during the period. 76.43% of the stock is currently owned by institutional investors and hedge funds.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Related posts

Leave a Comment

Today, The Celgene Corp. (CELG) Cut to “Hold” at Vetr Inc.

Today, The      Celgene Corp. (CELG) Cut to “Hold” at Vetr Inc.

Vetr downgraded shares of Celgene Corp. (NASDAQ:CELG) from a buy rating to a hold rating in a research report sent to investors on Monday. The firm currently has $125.81 price target on the biopharmaceutical company’s stock.

Several other analysts have also commented on the stock. Leerink Swann reaffirmed a market perform rating and set a $135.00 price target (up previously from $125.00) on shares of Celgene Corp. in a research report on Monday, August 1st. Stifel Nicolaus reaffirmed a buy rating and set a $138.00 price target on shares of Celgene Corp. in a research report on Tuesday, August 2nd. Morgan Stanley reaffirmed a hold rating and set a $120.00 price target on shares of Celgene Corp. in a research report on Wednesday, August 3rd. BTIG Research raised shares of Celgene Corp. from a neutral rating to a buy rating and lifted their price target for the company from $116.14 to $138.00 in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research raised shares of Celgene Corp. from a hold rating to a buy rating and set a $130.00 price target on the stock in a research report on Friday, August 5th. Four equities research analysts have rated the stock with a hold rating and twenty-seven have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $136.77.

Shares of Celgene Corp. (NASDAQ:CELG) opened at 118.51 on Monday. Celgene Corp. has a 12-month low of $93.05 and a 12-month high of $127.00. The firm’s 50-day moving average price is $108.88 and its 200-day moving average price is $106.73. The stock has a market cap of $91.87 billion, a price-to-earnings ratio of 45.01 and a beta of 1.71.

Celgene Corp. (NASDAQ:CELG) last released its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.48 by $0.10. Celgene Corp. had a net margin of 19.71% and a return on equity of 70.48%. The business had revenue of $2.98 billion for the quarter, compared to analyst estimates of $2.84 billion. During the same period last year, the company posted $1.23 EPS. The business’s revenue was up 27.8% on a year-over-year basis. On average, analysts forecast that Celgene Corp. will post $5.92 EPS for the current fiscal year.

In other Celgene Corp. news, Director Michael A. Friedman sold 18,600 shares of the stock in a transaction that occurred on Wednesday, November 9th. The shares were sold at an average price of $116.10, for a total transaction of $2,159,460.00. Following the transaction, the director now owns 18,600 shares of the company’s stock, valued at $2,159,460. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Corp /De/ Celgene purchased 800,150 shares of the business’s stock in a transaction on Monday, October 24th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $11,202,100.00. The disclosure for this purchase can be found here. Company insiders own 0.97% of the company’s stock.

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Celgene Corp. by 0.8% in the second quarter. Vanguard Group Inc. now owns 47,833,717 shares of the biopharmaceutical company’s stock worth $4,717,840,000 after buying an additional 395,600 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its position in Celgene Corp. by 2.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 20,712,785 shares of the biopharmaceutical company’s stock worth $2,165,107,000 after buying an additional 471,143 shares in the last quarter. Jennison Associates LLC increased its position in Celgene Corp. by 14.1% in the third quarter. Jennison Associates LLC now owns 15,921,002 shares of the biopharmaceutical company’s stock worth $1,664,222,000 after buying an additional 1,967,645 shares in the last quarter. BlackRock Fund Advisors increased its position in Celgene Corp. by 3.4% in the third quarter. BlackRock Fund Advisors now owns 15,575,165 shares of the biopharmaceutical company’s stock worth $1,628,072,000 after buying an additional 508,334 shares in the last quarter. Finally, Northern Trust Corp increased its position in Celgene Corp. by 2.5% in the third quarter. Northern Trust Corp now owns 10,714,220 shares of the biopharmaceutical company’s stock worth $1,119,957,000 after buying an additional 261,176 shares in the last quarter. 76.43% of the stock is currently owned by institutional investors.

About Celgene Corp.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Related posts

Leave a Comment